Thomas Schmelter

4PUBLICATIONS
7CO-AUTHORS
Vision scienceOptical technologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 21, 2025
Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration.

Paolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier

|Jul 14, 2025
Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

David M Brown, David S Boyer, Diana V Do

|Jan 06, 2024
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing.

Laurent Kodjikian, Lluís Arias Barquet, András Papp

|Apr 03, 2023
Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.

Jeffrey S Heier, Allen C Ho, David S Boyer

Pageof 1

Frequent Collaborators

1 joint publications

David S Boyer

1 joint publications

Laurent Kodjikian

1 joint publications

Peter J Kertes

1 joint publications

Rufino Silva